Phase 1/2 study of durvalumab and tremelimumab as monotherapy and in combination in patients with unresectable hepatocellular carcinoma (HCC) Meeting Abstract
| Authors: | Abou-Alfa, G. K.; Sangro, B.; Morse, M.; Zhu, A. X.; Kim, R. D.; Cheng, A. L.; Kudo, M.; Kang, Y. K.; Chan, S. L.; Antal, J.; Boice, J.; Xiao, F.; Morris, S. R.; Bendell, J. |
| Abstract Title: | Phase 1/2 study of durvalumab and tremelimumab as monotherapy and in combination in patients with unresectable hepatocellular carcinoma (HCC) |
| Meeting Title: | 52nd Annual Meeting of the American Society of Clinical Oncology (ASCO) |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 34 |
| Issue: | 15 Suppl. |
| Meeting Dates: | 2016 Jun 3-7 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2016-05-20 |
| Start Page: | 167s |
| Language: | English |
| ACCESSION: | WOS:000404665404140 |
| DOI: | 10.1200/JCO.2016.34.15_suppl.TPS3103 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: TPS3103 -- Source: Wos |
